Division of Breast Surgical Oncology, Department of Surgery, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Ann Surg Oncol. 2013 Oct;20(10):3294-302. doi: 10.1245/s10434-013-3174-4. Epub 2013 Aug 22.
Skin-sparing mastectomy (SSM) or nipple skin-sparing mastectomy (NSSM) are procedures commonly offered as part of the surgical treatment for breast cancer. Each involves a mastectomy with preservation of the skin overlying the breast (in SSM) and often also the skin overlying the nipple-areolar complex (NSSM). At the time of mastectomy, immediate reconstruction with a tissue expander or implant is performed for a more favorable cosmetic outcome. Until now, these procedures have been reserved for low-risk patients and are rarely offered to patients with advanced disease where neoadjuvant chemotherapy and postmastectomy radiation are a planned part of the treatment. We report our experience of SSM and NSSM in such high-risk patients.
This retrospective study from 2001 to 2012 evaluates the outcomes of 527 patients who underwent SSM or NSSM. Sixty patients with advanced disease who underwent neoadjuvant chemotherapy followed by SSM or NSSM with immediate reconstruction and subsequent radiotherapy (RT) were identified. The cosmetic and oncologic outcomes of this patient group were noted.
A total of 527 patients in our study group had a total of 1,035 skin-sparing mastectomies (558 NSSM and 477 SSM; 444 patients with bilateral and 83 with unilateral procedures). Of the 60 patients with locally advanced disease, 39 underwent NSSM and 21 underwent SSM. All patients received RT to the diseased side. Mean age of the group was 50.2 ± 10.8 years, with a range of 27-75 years for NSSM and 29-73 years for SSM. The lymph node status was positive in 71.8 % with an average tumor size of 3.8 ± 2.5 cm. The overall radiation-induced complication rate was 38.1 % (8 of 21) in the SSM group and 30.8 % (12 of 39) in the NSSM group. Wound infections and tissue necrosis occurred at a rate of 16.7 %. The implant was removed in 5 % of these cases. Capsular contracture occurred at a rate of 10.2 %. Radiation-related nonbreast complications occurred in 6.7 % of the cases. Examples of these radiation-related nonbreast complications included radiation pneumonitis, stenosis of the superior vena cava requiring venoplasty and severe atypical chest pain thought to be consistent with osteochondritis. The locoregional recurrence rate (median follow-up of 18 months) was 14.3 % (3 of 21) in the SSM group and 10.3 % (4 of 39) in the NSSM group.
SSM and NSSM have been offered to patients with relatively low-risk breast cancer as oncologically safe while affording superior cosmesis with one-step immediate reconstruction. Our series demonstrates that either procedure can be offered to patients with more advanced cancers requiring postoperative RT. The complication rates are comparable to those reported for patients undergoing RT after traditional mastectomies.
保乳皮肤切除术(SSM)或乳头皮肤保留乳房切除术(NSSM)是作为乳腺癌手术治疗的一部分常用的手术。两者均涉及乳房切除术,保留乳房表面的皮肤(在 SSM 中),通常还保留乳头乳晕复合体的皮肤(在 NSSM 中)。在乳房切除术中,同时进行组织扩张器或植入物的即刻重建,以获得更有利的美容效果。直到现在,这些手术一直保留给低危患者,很少提供给晚期疾病患者,因为新辅助化疗和乳房切除术后放疗是治疗计划的一部分。我们报告了我们在这些高危患者中进行 SSM 和 NSSM 的经验。
这项回顾性研究于 2001 年至 2012 年,评估了 527 例接受 SSM 或 NSSM 的患者的结局。确定了 60 例接受新辅助化疗后接受 SSM 或 NSSM 即刻重建和随后放疗(RT)的晚期疾病患者。记录了该患者组的美容和肿瘤学结局。
我们研究组的 527 例患者共进行了 1035 例保乳皮肤切除术(558 例 NSSM 和 477 例 SSM;444 例双侧,83 例单侧)。60 例局部晚期疾病患者中,39 例行 NSSM,21 例行 SSM。所有患者均接受了患侧 RT。该组的平均年龄为 50.2 ± 10.8 岁,NSSM 的年龄范围为 27-75 岁,SSM 的年龄范围为 29-73 岁。淋巴结状态阳性的比例为 71.8%,平均肿瘤大小为 3.8 ± 2.5cm。SSM 组的总体放射性并发症发生率为 38.1%(21 例中的 8 例),NSSM 组为 30.8%(39 例中的 12 例)。伤口感染和组织坏死的发生率为 16.7%。在这些病例中,5%的患者取出了植入物。包膜挛缩的发生率为 10.2%。有 6.7%的病例发生与放疗相关的非乳房并发症。这些与放疗相关的非乳房并发症的例子包括放射性肺炎、上腔静脉狭窄需要血管成形术和严重的非典型胸痛,认为与骨软骨炎一致。SSM 组的局部区域复发率(18 个月的中位随访)为 14.3%(21 例中的 3 例),NSSM 组为 10.3%(39 例中的 4 例)。
SSM 和 NSSM 已提供给具有相对较低风险的乳腺癌患者,在进行一步即刻重建时具有良好的美容效果,同时具有肿瘤安全性。我们的研究表明,这两种手术都可以提供给需要术后 RT 的更晚期癌症患者。并发症发生率与接受传统乳房切除术 RT 的患者报告的发生率相当。